^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD3 agonist

    Related drugs:
    3d
    Clinical Study of (A-319) in the Treatment of Active Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=12, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P1 trial
    |
    CRP (C-reactive protein)
    |
    A-319
    4d
    A Study of GR1803 in Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1/2, N=44, Recruiting, Genrix (Shanghai) Biopharmaceutical Co., Ltd.
    New P1/2 trial
    4d
    Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use. (PubMed, Clin Lung Cancer)
    Tarlatamab is associated with higher CRS and ICANS rates in real-world settings than observed in trials. Prophylactic tocilizumab may mitigate these toxicities in high-risk patients and should be considered for incorporation into treatment protocols.
    Journal • Real-world evidence
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    LDH elevation
    |
    Imdelltra (tarlatamab-dlle) • Actemra IV (tocilizumab)
    4d
    Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study. (PubMed, BMC Med)
    IBI389 showed manageable safety profiles in patients with advanced solid tumors and preliminary efficacy in Claudin18.2-positive patients with GC/GEJC.
    P1 data • Journal
    |
    CLDN18 (Claudin 18)
    |
    IBI-389
    5d
    EPCORE DLBCL-3: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=111, Active, not recruiting, Genmab | Trial completion date: Jul 2027 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    lenalidomide • Epkinly (epcoritamab-bysp)
    5d
    Glofitamab in Real Life (clinicaltrials.gov)
    P=N/A, N=250, Recruiting, The Lymphoma Academic Research Organisation | Not yet recruiting --> Recruiting | Trial completion date: Nov 2026 --> Jul 2026 | Initiation date: Aug 2025 --> Dec 2025 | Trial primary completion date: Nov 2025 --> Mar 2026
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    Columvi (glofitamab-gxbm)
    6d
    Circulating Tumor Cells Predict Response to the DLL3-targeting Bispecific Antibody Tarlatamab. (PubMed, Cancer Discov)
    Acquired resistance to tarlatamab is associated in some cases with loss of DLL3 expression, but persistence of other targetable neuro-endocrine epitopes; in other patients, DLL3 is retained on CTCs, but accompanied by systemic markers of T cell dysfunction. Quantitation of DLL3-positive CTCs identifies patients likely to benefit from tarlatamab, and longitudinal monitoring may guide therapeutic decision-making at the time of acquired resistance.
    Journal • Circulating tumor cells
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression • DLL3 positive
    |
    Imdelltra (tarlatamab-dlle)
    6d
    A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=750, Recruiting, Amgen | Trial primary completion date: Aug 2028 --> Jan 2030
    Trial primary completion date
    |
    docetaxel • abiraterone acetate • cabazitaxel • xaluritamig (AMG 509)
    7d
    A041703: Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=64, Suspended, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    7d
    An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=28, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting --> Recruiting | N=19 --> 28 | Trial completion date: Nov 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    8d
    Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 positive
    |
    PIT565
    8d
    Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    Tecvayli (teclistamab-cqyv)